UA98605C2 - Novel method for preventing or treating m. tuberculosis infection - Google Patents
Novel method for preventing or treating m. tuberculosis infectionInfo
- Publication number
- UA98605C2 UA98605C2 UAA200711587A UAA200711587A UA98605C2 UA 98605 C2 UA98605 C2 UA 98605C2 UA A200711587 A UAA200711587 A UA A200711587A UA A200711587 A UAA200711587 A UA A200711587A UA 98605 C2 UA98605 C2 UA 98605C2
- Authority
- UA
- Ukraine
- Prior art keywords
- tuberculosis infection
- fusion protein
- preventing
- treating
- mtb72f
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 4
- 201000008827 tuberculosis Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000007420 reactivation Effects 0.000 abstract 1
- 238000004904 shortening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67654905P | 2005-04-29 | 2005-04-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA98605C2 true UA98605C2 (en) | 2012-06-11 |
Family
ID=40006338
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200711587A UA98605C2 (en) | 2005-04-29 | 2006-04-27 | Novel method for preventing or treating m. tuberculosis infection |
| UAA201111598A UA107788C2 (en) | 2005-04-29 | 2006-04-27 | A fusion protein of m. tuberculosis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201111598A UA107788C2 (en) | 2005-04-29 | 2006-04-27 | A fusion protein of m. tuberculosis |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN105903008B (en) |
| UA (2) | UA98605C2 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2133100B1 (en) * | 2000-06-20 | 2011-10-05 | Corixa Corporation | MTB32A Antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof |
| US20030175294A1 (en) * | 2001-03-13 | 2003-09-18 | Corixa Corporation | Heterologous fusion protein constructs comprising a Leishmania antigen |
| AU2003213118A1 (en) * | 2002-02-15 | 2003-09-09 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
-
2006
- 2006-04-27 UA UAA200711587A patent/UA98605C2/en unknown
- 2006-04-27 UA UAA201111598A patent/UA107788C2/en unknown
- 2006-04-27 CN CN201610086198.9A patent/CN105903008B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN105903008A (en) | 2016-08-31 |
| UA107788C2 (en) | 2015-02-25 |
| CN105903008B (en) | 2020-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013502449A1 (en) | Novel method for preventing or treating m tuberculosis infection | |
| CY1110886T1 (en) | COMPOSITIONS FOR COMBATING RESISTANCE TO B-LACTAMA MEDIUM-TREATED ANTIBODIES, USING B-LAKTAMASIS USES | |
| TW200630093A (en) | Dose forms | |
| CO5700796A2 (en) | COMPOSITIONS CONTAINING PIPERACILIN AND TAZOBACTAM USEFUL FOR INJECTIONS | |
| BRPI0415953B8 (en) | controlled release dosage formulation and set of controlled release dosage forms | |
| NO20071711L (en) | Compositions containing piperacillin, tazobactam and an amino carboxylic acid in a sodium lactate diluent | |
| EA201490378A1 (en) | TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β | |
| PE20190351A1 (en) | HUNTER'S SYNDROME THERAPEUTIC AGENT AND METHOD OF TREATMENT | |
| ECSP044985A (en) | SINGLE DOSE AZITHROMYCIN FOR RESPIRATORY INFECTIONS | |
| EA200501821A1 (en) | PHARMACEUTICAL COMBINATION, CONTAINING MODAFINIL AND OTHER DRUG PREPARATION | |
| UA99094C2 (en) | Method for the treatment of patients with autoantibody positive disease | |
| WO2005030109A3 (en) | Regimen for the administration of rifamycin-class antibiotics | |
| EA200401303A1 (en) | MEDICINES CONTAINING STEROIDS AND NEW ANTICHOLINERGIC MEANS | |
| UA98605C2 (en) | Novel method for preventing or treating m. tuberculosis infection | |
| ATE315041T1 (en) | SALT OF MORPHINE-6-GLUCURONIDE | |
| CY1115823T1 (en) | NEW METHOD FOR PREVENTION OR TREATMENT OF INFECTION M. TUBERCULOSIS | |
| WO2005082396A3 (en) | Use of mda-7 to inhibit infection by pathogenic organisms | |
| DK1677808T3 (en) | Combination preparation for the treatment of sepsis | |
| TH1701007800A (en) | Metallo-beta-lactamase inhibitor | |
| WO2015027040A3 (en) | Methods and compositions for treating schistosome infection |